Sign in

NCT04151134Active, not recruiting

Evaluation of Tongue Base MucOsectomy & Step sErial Sectioning

Evaluation of the Role of Tongue Base MucOsectomy and Step sErial Sectioning in the Management of the Unknown Primary Squamous Cell Cancer in the Head and Neck

Source: ClinicalTrials.gov · Last updated 12 Feb 2026

Brief summary (registry, in English)

Squamous cell carcinoma (SCC) is a cancer that originates from the cells lining the body and can spread into the lymph glands and beyond. Some patients first present with an SCC which has moved to the lymph glands of the neck. Clinical examination and imaging investigations are performed to try and identify the site where the cancer has originated. However, if no original site can be identified, then the investigators call these 'cancers of an unknown primary' (CUP) of the head and neck. One region where these cancers could have originated from is the oropharynx. There are two areas in the oropharynx were cancers commonly arise. One area is the palatine tonsils, which can be removed for analysis with an operation called tonsillectomy. The other area is the tissue lining the back of the tongue, known as the tongue base. A relatively new surgical technique called 'tongue base mucosectomy' (TBM) allows removal of this tissue to see if the primary cancer is contained within it. This study will then use a histological method called 'step serial sectioning' (SSS) to look in more detail at the tonsils and tongue base, hoping to increase the detection rate of the primary cancer. Centres performing TBM will be asked to participate. Patients will be asked to consent to their tissue being used for SSS after it has undergone conventional histology. Anonymised samples will be sent to a central laboratory in Newcastle for processing. Other anonymised data regarding the patients' diagnosis and care will be collated. Patients will be asked to complete questionnaires regarding pain and swallowing recovery following surgery. A smaller cohort of patients will also be interviewed as part of a qualitative research process to establish their views on CUP and the acceptability of the above treatment.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
100 (estimated)
First submitted
10 Oct 2019
Start date
1 Nov 2019
Primary completion date
1 Dec 2029
Lead sponsor
Royal Marsden NHS Foundation Trust
NCT number
NCT04151134

What you commit to

  • Study type: Observational
  • Planned participants: 100
  • From 1 Nov 2019 to the primary completion date, 1 Dec 2029
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Primary site identified by any means prior to being indicated for TBM
  • Patients known to have a history of previous H\&N cancers
  • Patients known to have undergone previous radiation to the H\&N region

Other

  • Patients undergoing targeted biopsies or resections

Who the study is looking for

  • Aged 16 or over
  • Both sexes
  • Cervical metastatic SCC, confirmed with cytology or biopsy, undergoing TBM for identification of primary site

Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
University Hospitals Birmingham NHS Foundation Trust
Coordinator of this site? Confirm its status
BirminghamUnited KingdomUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.